Alzheimer’s Disease (AD) is the most common form of dementia, affecting around 520,000 people in the UK. A hallmark feature of AD is the build-up of abnormal plaques of the amyloid beta protein in the brain which can damage neurons, leading to cell death and the changes in behaviour and cognition associated with the disease. […]
Many women think of the menopause with dread, associating it with uncontrolled body temperature and hormonal shifts. In fact, 1 in 10 women report hot flushes as intolerable, severely impairing their quality of life and daily wellbeing. The most widespread solution to counteract menopausal flushes is oestrogen supplementation (also known as hormone replacement therapy, HRT) […]
Chronic myeloid leukaemia (CML) is a type of cancer where too many white blood cells are produced. It remained a serious life-threatening condition until tyrosine kinase inhibitor (TKI) therapy transformed the outcomes of patients with this disease. Most of these patients are now expected to live a normal lifespan, provided they continue TKI treatment for […]
DeviceDiagnosticInnovation New technology could revolutionise the detection of blood-borne infections
A device with the potential to revolutionise the diagnosis and treatment of sepsis has been unveiled at an Imperial College/Royal Institution Technology vs Infectious Disease summit showcasing the best in British technology in combating global infection. Sepsis is a potentially life-threatening condition caused by bloodstream infections which can lead to multiple organ failure, proving fatal […]
Gestational trophoblastic neoplasia is a collective term for a number of malignant pregnancy-related disorders, such as choriocarcinoma and placental site trophoblastic tumours that invade locally or metastasise. This disease affects approximately 18,000 women globally every year, and is treated with chemotherapy, using human chorionic gonadotropin (hCG) in serum as a sole response biomarker. However even […]
Harnessing world-leading discovery science and clinical expertise to develop innovative therapeutics, devices and diagnostics for healthcare
The NIHR Imperial Biomedical Research Centre (BRC) is a translational research partnership between Imperial College London and Imperial College Healthcare NHS Trust. It provides the infrastructure – human and technological – to conduct early stage experimental medicine within our Academic Health Science Centre. The BRC aims to exploit the scientific power of the College’s Faculties of Medicine, Engineering and Natural Sciences, and provide proof-of-principle of new breakthroughs within the clinical setting. We collaborate extensively with industry, other funding agencies, and with colleagues across the NIHR infrastructure. Our patients and volunteers are closely involved in the design and delivery of research, and the BRC invests heavily in skills and training for the clinical academics of tomorrow.
Examples of research projects testing out new drugs, devices and diagnostics in humans for the first time. The BRC is specifically aimed at supporting these kinds of experimental medicine studies.
The NIHR Imperial BRC has developed a range of innovative device technologies, in collaboration with scientists in our Faculties of Natural Sciences and Engineering. Some of the most recent are highlighted here.
A selection of short films explaining more about key parts of the BRC infrastructure and some of the innovative directions our research is moving into.